Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ONCOS-102 + cyclophosphamide + pemetrexed + carboplatin
- Development stage
- Unknown
- Lead developer
- Targovax
- Modality
- Small Molecules, Oncolytic Viruses → Oncolytic Therapeutics
- Administration
- Intratumoral (ONCOS-102)[5][7], Intravenous (cyclophosphamide, Pemetrexed, Carboplatin)[5]
01
Overview
ONCOS-102 + cyclophosphamide + pemetrexed + carboplatin is a combination regimen for cancer treatment consisting of ONCOS-102, an oncolytic adenovirus genetically engineered to selectively replicate in and lyse cancer cells (particularly those with p16/Rb-defective pathways), while expressing the immunostimulatory cytokine GM-CSF to enhance antitumor immune responses, paired with cyclophosphamide (an alkylating agent), pemetrexed (an antifolate antimetabolite), and carboplatin (a platinum-based chemotherapeutic). The combination aims to leverage direct oncolysis, immunomodulation, and cytotoxic chemotherapy for synergistic anticancer effects[1][2][3][5][7]. ONCOS-102 has shown in trials to remodel the tumor microenvironment, increasing T-cell infiltration and activating proinflammatory genes, while cyclophosphamide, pemetrexed, and carboplatin are established chemotherapeutics for malignant pleural mesothelioma and other cancers[5][7].
- Other names
- Ad5/3-D24-GMCSFCGTG-102CGTG102CGTG 102
02
Targets
TS (Thymidylate synthase)DHFR (Dihydrofolate reductase)DNAGART (GAR transformylase)
Beyond the preview
Go deeper on ONCOS-102 + cyclophosphamide + pemetrexed + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ONCOS-102 + cyclophosphamide + pemetrexed + carboplatin.